In 2000 Antonio Criminisi obtained his doctorate degree (PhD) in computer vision from the University of Oxford. In June 2000 Antonio joined the Machine Learning and Perception group at Microsoft Research in Cambridge as a visiting researcher. In February 2001, he moved to the Interactive Visual Media Group in Redmond (WA, USA) as a post-doctorate researcher. In October 2002, he moved back to the Microsoft Research Cambridge as a Researcher. In 2014, he became Principal Researcher and is now leading Project InnerEye, to develop a tool for assistive AI for cancer treatment.
Antonio has written and co-authored numerous scientific papers and books on machine learning for the analysis of radiological images, decision forests, deep learning and convolutional neural networks, object recognition, image and video analysis and editing, videoconferencing, 3D reconstruction and virtual/augmented reality, forensic science and history of art.
Antonio's research has been awarded a number of best paper prizes in top computer vision and machine learning conferences, amongst which the prestigious David Marr prize at ICCV 2015 for his paper "Deep Neural Decision Forests".

Further Information
http://research.microsoft.com/~antcrim/
https://www.microsoft.com/en-us/research/project/medical-image-analysis/

Peyman Gifani, obtained his PhD from the University of Cambridge, Department of Engineering. He then gained a Cambridge/ Wellcome Trust Senior Interdisciplinary Research fellowship to work jointly in the Cambridge Systems Biology Centre (Department of Genetics) and the Machine Intelligence Laboratory, (Department of Engineering). Through his career, he has gained multidisciplinary experience in areas including systems and synthetic biology, drug discovery, nonlinear dynamical systems, machine learning and AI. He is a former committee member of the Cambridge University Entrepreneurs (CUE). Prior to his PhD, he co-founded a biotech company that won several awards.

He is the founder and CEO of AI VIVO as a Cambridge, UK-based company with a unique computational platform to accelerate drug discovery via intelligent systems pharmacology. AI VIVO provides an innovative methodology that captures nonlinear dynamics hidden in biological data and translates them to novel unexpected discoveries. To achieve predictions with unparalleled accuracy, a proprietary data representation algorithm unfolds insightful data associated with diseases, drugs, and targets as input to our optimised prediction engine powered by artificial intelligence (AI). Using the AI prediction engine, AI VIVO develops a portfolio of IP-protected, pre-clinical discovery programmes as differentiated assets with a much higher probability of clinical success.

Jaime has experience in digital healthcare development and building personal medicine company strategies having led public relations and communication strategy, e-health platform development, corporate and business development in various companies. Gaining major international experience working on commercialisation and consultancy projects in the biotech and hi-tech industry, with multinational colleagues, and having access to a large global alumni network within the life sciences and software fields, the adaptability and exposure to global work methods differentiates the assets Jaime can bring to any business focussing on connected, digital applications to impact society for the better.

A qualified lawyer and nurse and longstanding member of an NHS Research Ethics Committee, Alison leads PHG Foundation’s regulation and ethics team. Recent work includes advocacy on data and device regulation that impacts innovations in healthcare. This includes appraising the impact of regulatory changes to EU data protection and medical devices regulation for clinical genetics services and medical research; working with stakeholders and statutory authorities to facilitate optimal data sharing policies in the NHS; and assessing how existing and future in vitro diagnostic devices regulation might impact on IVD device and software development.